Cybin Corp will become the latest psychedelics company to go public, via RTO.
Psychedelics Investing 101: Basic Investing Tips
Psychedelic drugs are an emerging sector with exciting investment potential. Here are some tips on beginning your due diligence.
Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus
New psychedelics company specializing in psilocybin-based medical research has filed a prospectus.
Numinus Positioned To Be Significant Player In Psilocybin R&D
Numinus Wellness is building a deep R&D platform for psilocybin-based drug research.
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
MindMed has filed two patent applications relating to technologies to screen and optimize dosing of MDMA and LSD.
Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
Psychedelics micro-dosing offers several key advantages in commercializing psychedelics drugs.
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI LIfe Sciences is about to add three new R&D partners to its industry-leading psychedelics research platform.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its psychedelics clinical trials
Red Light Holland Announces the Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised CAD$3,830,529 in its latest financing.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
